Newsroom | 28110 results

Venlo, Niederlande--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute die Ernennung von Jonathan M. Pratt zum Vorstandsvorsitzenden mit Wirkung zum 1. September 2026 bekannt gegeben. Er bringt mehr als 25 Jahre internationale Führungserfahrung in den Bereichen Life Sciences, Labortechnologien und Gesundheitswesen ins Unternehmen ein. Jon Pratt war zuletzt Präsident und Vorstandsvorsitzender der Filtration Group und führte das Unternehmen bis zum Abschluss des Ve...

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Jonathan M. Pratt has been appointed Chief Executive Officer, effective September 1, 2026. He brings to QIAGEN more than 25 years of international leadership experience across life sciences, laboratory technologies and healthcare. Jon Pratt most recently served as President and CEO of Filtration Group, leading the business through the completion of its sale to Parker-Hannifin Corpor...

SALT LAKE CITY--(BUSINESS WIRE)--Carterra®, a leading provider of high-throughput surface plasmon resonance (HT-SPR) platforms for antibody and small molecule drug discovery, today highlighted the role of Carterra HT-SPR in one of the largest published wet-lab validations of AI-designed proteins to date. In a study released August 18, 2026, Anthropic reported that its Claude models autonomously ran de novo protein binder design campaigns against 15 challenging targets — researching each target,...

TAUNTON, Mass.--(BUSINESS WIRE)--Copia Scientific announces a new distribution partnership with HSE•AG, expanding access to innovative automated microplate analysis solutions....

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Tempus ECG-PH (pulmonary hypertension), an AI-enabled software device that analyzes standard 12-lead electrocardiograms (ECGs) for signs associated with pulmonary hypertension. Tempus ECG-PH is the third FDA-cleared device in Tempus’ growing cardiovascular portfolio, expanding the company’s suite of next-generation AI products aimed at ide...

CARMEL, Ind.--(BUSINESS WIRE)--New report reveals a growing healthcare data trust gap, with poor-quality patient data creating challenges for interoperability and care....

SEATTLE--(BUSINESS WIRE)--TwinStrand Biosciences (TwinStrand), the pioneer in Duplex Sequencing® technology, today announced that the U.S. District Court for the District of Delaware entered final judgment on Aug. 21, 2026, in favor of TwinStrand and the University of Washington (UW) in their patent infringement suit against Guardant Health, Inc. (Nasdaq: GH). The final judgment preserves a November 2023 jury verdict finding that Guardant Health willfully infringed two core patents underlying T...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the dosing of the first patient in August in the Phase 1/2 FUNCTION-DMD clinical trial evaluating PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD). PBGENE-DMD is Precision's wholly owned in vivo gene editing program designed to durab...

MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization...

BANGKOK--(BUSINESS WIRE)--InterSystems, a creative data technology provider managing over one billion healthcare records globally, will bring healthcare leaders from across Asia to Bangkok for InterSystems Asia READY 2026, where the focus will be on how trusted data, interoperability, and practical artificial intelligence (AI) can accelerate smarter healthcare delivery and strengthen Thailand's position as a regional medical hub. As Thailand continues investing in digital health, hospitals, ins...